[go: up one dir, main page]

UA97696U - METHOD OF PREVENTING CHILD DEVELOPMENT IN CHILDREN - Google Patents

METHOD OF PREVENTING CHILD DEVELOPMENT IN CHILDREN

Info

Publication number
UA97696U
UA97696U UAU201412505U UAU201412505U UA97696U UA 97696 U UA97696 U UA 97696U UA U201412505 U UAU201412505 U UA U201412505U UA U201412505 U UAU201412505 U UA U201412505U UA 97696 U UA97696 U UA 97696U
Authority
UA
Ukraine
Prior art keywords
children
drops
day
years
treatment
Prior art date
Application number
UAU201412505U
Other languages
Russian (ru)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to UAU201412505U priority Critical patent/UA97696U/en
Publication of UA97696U publication Critical patent/UA97696U/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Спосіб попередження розвитку уражень печінки у дітей включає застосування антибактеріальної терапії, причому додатково протягом всього курсу лікування призначають препарат "Галстена" в разовій дозі для дітей старше 12 років по 10 крапель або 1 таблетці, дітям віком 5-12 років - по 5-7 крапель або 1/2 таблетки, дітям 2-4 років - по 2-4 краплі і дітям молодше двох років - по 1 краплі, кратність прийому в перші два дні лікування для крапель - до 8 разів на добу, для таблеток - до 4 разів на добу, з 3-го дня лікування краплі призначають в разових дозах 3 рази на добу, таблетки - 2 рази на добу.A method of preventing the development of liver damage in children involves the use of antibacterial therapy, and additionally throughout the course of treatment prescribe the drug "Galsten" in a single dose for children over 12 years of 10 drops or 1 tablet, children aged 5-12 years - 5-7 drops or 1/2 tablet, children 2-4 years - 2-4 drops and children under two years - 1 drop, the frequency of taking the first two days of treatment for drops - up to 8 times a day, for tablets - up to 4 times day, from the 3rd day of treatment drops are prescribed in single doses 3 times a day y, tablets - 2 times a day.

UAU201412505U 2014-11-21 2014-11-21 METHOD OF PREVENTING CHILD DEVELOPMENT IN CHILDREN UA97696U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201412505U UA97696U (en) 2014-11-21 2014-11-21 METHOD OF PREVENTING CHILD DEVELOPMENT IN CHILDREN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201412505U UA97696U (en) 2014-11-21 2014-11-21 METHOD OF PREVENTING CHILD DEVELOPMENT IN CHILDREN

Publications (1)

Publication Number Publication Date
UA97696U true UA97696U (en) 2015-03-25

Family

ID=53501269

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201412505U UA97696U (en) 2014-11-21 2014-11-21 METHOD OF PREVENTING CHILD DEVELOPMENT IN CHILDREN

Country Status (1)

Country Link
UA (1) UA97696U (en)

Similar Documents

Publication Publication Date Title
MX378273B (en) ACTIVE COMPOUNDS TOWARDS BROMODOMAINS.
MX365939B (en) Nuclear transport modulators and uses thereof.
HUE049341T2 (en) Substituted indazoles, process for their preparation, pharmaceutical preparations containing them and their use in the preparation of pharmaceutical preparations
MX2020009780A (en) Autotaxin inhibitor compounds.
EP3311376C0 (en) Devices and methods for drug administration and mixing, as well as training in the correct techniques therefor
NZ746338A (en) Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
WO2014121137A3 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
MX2017003216A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients.
DK3452100T3 (en) PHARMACEUTICAL CARRIERS CONTAINING MIRNAUES FOR USE IN THE TREATMENT OF FIBROTIC DISEASES CAUSED BY HYPERGLYCHEMIA
CY1119532T1 (en) (S) -PYRILDOL AND THE PHARMACEUTALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
EP3137204C0 (en) PHARMACY FORMULATION MANUFACTURING SYSTEM AND PHARMACY FORMULATION MANUFACTURING METHOD FOR PRODUCING INDIVIDUAL PHARMACEUTICAL FORMULATURES
MX389474B (en) DIMETHYL FUMARATE AND VACCINATION REGIMEN.
MX364528B (en) Withanolides useful for the treatment of neurodegenerative diseases.
CY1119522T1 (en) (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX371343B (en) Liver x receptor (lxr) modulators.
MX2016002930A (en) Liver x receptor (lxr) modulators.
UA97696U (en) METHOD OF PREVENTING CHILD DEVELOPMENT IN CHILDREN
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
FR3021219B1 (en) OLIGO-PORPHYRANES, METHOD AND MEDICINAL PRODUCT
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer
PL2996675T3 (en) Pharmaceutical formulation, process for preparing the pharmaceutical formulation and infusion solution and use thereof as medicinal product and/or as pharmaceutical
PH12020500472A1 (en) Autotaxin inhibitor compounds
UA91737U (en) Method for treating irritated bowel syndrome in children